FARON PHARMACEUTICALS OY
Clinical-stage biopharmaceutical company developing immunotherapies for cancer.
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Manufacturing
Description
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-24 08:00 |
Faron announces acceptance of bexmarilimab Phase II data for oral presentation …
|
English | 10.2 KB | ||
| 2025-04-15 08:00 |
Inside Information: Faron Announces Positive Phase II results in higher-risk my…
|
English | 7.5 KB | ||
| 2025-03-27 08:00 |
Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 A…
|
English | 7.3 KB | ||
| 2025-03-20 08:00 |
Shareholders’ Nomination Board updates its recommendation on the number of Boar…
|
English | 7.0 KB | ||
| 2025-03-03 13:05 |
FDA Grants Orphan Drug Designation
|
English | 15.5 KB | ||
| 2025-02-28 13:00 |
Notice of Annual General Meeting
|
English | 37.4 KB | ||
| 2025-02-27 08:30 |
Positive EMA Opinion on Orphan Drug Designation
|
English | 16.5 KB | ||
| 2025-02-27 08:15 |
Annual Report 2024 published
|
English | 14.7 KB | ||
| 2025-02-27 08:00 |
Financial Statement 1 January to 31 December 2024
|
English | 183.6 KB | ||
| 2025-02-19 11:00 |
Notice of Financial Statement and Annual Report
|
English | 15.3 KB | ||
| 2025-02-14 13:00 |
Holding(s) in Company
|
English | 53.1 KB | ||
| 2025-02-11 08:30 |
Change of Broker
|
English | 7.8 KB | ||
| 2025-02-06 16:00 |
Holding(s) in Company
|
English | 52.6 KB | ||
| 2025-02-06 08:00 |
Results of Oversubscribed Placing
|
English | 34.0 KB | ||
| 2025-02-05 17:30 |
Proposed Issue and Placing
|
English | 46.7 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FARON PHARMACEUTICALS OY
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
